GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    POS1357 OCULAR SCLERAL PATHOLOGY. UNDERLYING DISEASES AND SYSTEMIC TREATMENT. STUDY OF 175 PATIENTS FROM A SINGLE UNIVERSITY CENTER
    BMJ ; 2021
    In:  Annals of the Rheumatic Diseases Vol. 80, No. Suppl 1 ( 2021-06), p. 960.3-961
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 80, No. Suppl 1 ( 2021-06), p. 960.3-961
    Abstract: Ocular scleral pathology (OSP) includes episcleritis and scleritis. Episcleritis is generally a benign disease with a self-limited course, while scleritis is a more severe ocular condition. In some severe and refractory cases systemic therapy may be required. Objectives: In a wide series with OSP our aim was to assess a ) underlying diseases and b ) systemic treatment. Methods: Study of unselected all consecutive patients studied in a single University Hospital during the last ten years with : a ) episcleritis and b ) scleritis diagnosed by clinical features and slit-lamp (Watson and Hayreh criteria). Best corrected visual acuity (BCVA) and intraocular pressure (IOP) were measured at diagnosis and after systemic treatment. Results: We studied 175 patients (106 women/ 69 men) /212 affected eyes with OSP (episcleritis=135; scleritis=40); mean age 48.9±14.2 years. OSP was unilateral in 138 (78.9%), recurrent in 74 (42.9%) and chronic in 21 (12%). Most of them were idiopathic (n=81, 46.3%) while associated with IMID were 43.4% (Table 1). The most important underlying IMID were spondyloarthritis and inflammatory bowel disease, without significant differences between scleritis and episcleritis. Granulomatosis with polyangiits and systemic lupus erythematosus were more frequent in scleritis, not reaching statistical significance. Regarding treatment, topical treatment was used in all patients. 41.1% received systemic treatment, including systemic glucocorticoids, cDMARDS and bDMARDs. Systemic glucocorticoids and Methotrexate were used more frequently in scleritis (Table 1). The main indication for biologic therapy was related to underlying IMID in both groups, but 7 bDMARDs in scleritis were indicated for systemic and ocular compromise. BVCA and IOP improved significantly after systemic treatment in scleritis (Figure 1). Figure 1. BVCA and IOP at diagnosis and last visit. Conclusion: OSP is a relatively frequent entity. It is necessary to exclude an underlying systemic disease to establish correct systemic treatment. Table 1. Underlying diseases and systemic treatment. Overall (n =175 ) Episcleritis (n=135 ) Scleritis (n=40 ) p Age (years), mean ± SD 48.9 ± 14.2 47.8 ± 14.3 52.6 ± 13.9 0.061 Sex (women), n (% ) 106 (60.6) 81 (60) 25 (62.5) 0.920 UNDERLYING DISEASE -Idiopathic, n (% ) 81 (46.3) 65 (48.1) 16 (40) 0.364 -Infectious, n (% ) 11 (6.3) 7 (5.2) 4 (10) 0.276 -IMID, n (% ) 76 (43.4) 57 (42.2) 19 (47.5) 0.563 ∘Spondyloarthritis 21 (12) 17 (12.6) 4 (10) 0.787 ∘Crohn’s disease 16 (9.1) 14 (10.4) 2 (5) 0.469 ∘Rheumatoid Arthritis 14 (8) 12 (8.9) 2 (5) 0.740 ∘Granulomatosis with polyangiits 7 (4) 3 (2.2) 4 (10) 0.080 ∘Relapsing polychondritis 6 (3.4) 4 (3) 2 (5) 0.621 ∘Systemic lupus erythematosus 5 (2.9) 2 (1.5) 3 (7.5) 0.079 ∘Ulcerative colitis 3 (1.7) 2 (1.5) 1 (2.5) 0.796 SYSTEMIC TREATMENT 72 (41.1) 37 (27.4) 35 (87.5) 0.000* -Systemic glucocorticoids, n (% ) 72 (41.1) 37 (27.4) 35 (87.5) 0.000* -Methotrexate, n (% ) 39 (22.3) 17 (12.6) 22 (55) 0.000* -Non-methotrexatecDMARD, n (% ) 35 (20) 24 (17.8) 11 (27.5) 0.177 -TNFibDMARD, n (% ) 27 (15.4) 19 (14.1) 8 (20) 0.362 -Non-TNFibDMARD, n (% ) 8 (4.6) 5 (3.7) 3 (7.5) 0.386 *p 〈 0,05 *p 〈 0,05 Disclosure of Interests: Lara Sanchez-Bilbao: None declared, Vanesa Calvo-Río Speakers bureau: AbbVie, Lilly, Celgene, Grünenthal and UCB Pharma., Grant/research support from: MSD and Roche, José Luis Martín-Varillas: None declared, Carmen Álvarez-Reguera: None declared, Alba Herrero-Morant: None declared, Iñigo González-Mazón: None declared, Rosalía Demetrio-Pablo: None declared, Miguel A González-Gay Speakers bureau: AbbVie, Pfizer, Roche, Sanofi, Celgene and MSD. Ricardo, Grant/research support from: AbbVie, MSD, Jansen and Roche, Ricardo Blanco Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD., Grant/research support from: AbbVie, MSD and Roche
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2021-eular.2731
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2021
    detail.hit.zdb_id: 1481557-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Indicator condition-guided HIV testing with an electronic prompt in primary healthcare: a before and after evaluation of an intervention
    BMJ ; 2019
    In:  Sexually Transmitted Infections Vol. 95, No. 4 ( 2019-06), p. 238-243
    Details
    In: Sexually Transmitted Infections, BMJ, Vol. 95, No. 4 ( 2019-06), p. 238-243
    Abstract: Indicator condition (IC)-guided HIV testing is a strategy for the diagnosis of patients with HIV. The aim of this study was to assess the impact on the proportion of HIV tests requested after the introduction of an electronic prompt instructing primary healthcare (PHC) physicians to request an HIV test when diagnosing predefined IC. Methods A prospective interventional study was conducted in 2015 in three PHC centres in Barcelona to assess the number of HIV test requests made during the implementation of an electronic prompt. Patients aged 18–65 years without HIV infection and with a new diagnosis of predefined IC were included. The results were compared with preprompt (2013) and postprompt data (2016). Results During the prompt period, 832 patients presented an IC (median age 41.6 years [IQR 30–54], 48.2% female). HIV tests were requested in 296 individuals (35, 6%) and blood tests made in 238. Four HIV infections were diagnosed (positivity rate 1.7%, 95% CI 0.5% to 4.4%). The number of HIV tests requested based on IC increased from 12.6% in 2013 to 35.6% in 2015 (p 〈 0.001) and fell to 17.9% after removal of the prompt in 2016 (p 〈 0.001). Younger patient age (OR 0.97, 95% CI 0.96 to 0.98), birth outside Spain (OR 1.53, 95% CI 1.06 to 2.21) and younger physician age (OR 0.97, 95% CI 0.96 to 0.99) were independent predictive factors for an HIV test request during the prompt period. The electronic prompt (OR 3.36, 95% CI 2.70 to 4.18) was the factor most closely associated with HIV test requests. It was estimated that 10 (95% CI 3.0 to 26.2) additional new cases would have been diagnosed if an HIV test had been performed in all patients presenting an IC. Conclusions A significant increase in HIV test requests was observed during the implementation of the electronic prompt. The results suggest that this strategy could be useful in increasing IC-guided HIV testing in PHC centres.
    Type of Medium: Online Resource
    ISSN: 1368-4973 , 1472-3263
    URL: Article
    DOI: 10.1136/sextrans-2018-053792
    Language: English
    Publisher: BMJ
    Publication Date: 2019
    detail.hit.zdb_id: 2027968-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    AB0397 EPIDEMIOLOGY AND CLINICAL FEATURES OF OPHTHALMOLOGICAL MANIFESTATIONS IN BEHÇET’S DISEASE. STUDY OF 50 PATIENTS OF A SERIES OF 120 PATIENTS IN A REGION IN NORTHERN SPAIN
    BMJ ; 2021
    In:  Annals of the Rheumatic Diseases Vol. 80, No. Suppl 1 ( 2021-06), p. 1226-1227
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 80, No. Suppl 1 ( 2021-06), p. 1226-1227
    Abstract: Ophthalmological involvement is one of the most feared manifestations of Behçet’s disease [1-6]. Objectives: Our aim was to define the main demographic and clinical features of ophthalmological involvement in a well-defined cohort of patients with Behçet’s disease. Methods: Descriptive study of a cohort of 120 patients diagnosed with Behçet’s disease from January 1, 1980 to December 31, 2019. Finally, following the 2014 International Criteria for Behçet’s Disease (ICBD) ( J Eur Acad Dermatol Venereol 2014; 28:338-47 ) 94 patients were chosen for this study. Results: 50 patients (28 men/22 women; male to female ratio of 1:0.8) had ocular involvement. Mean age at diagnosis was 37.6±11.8 years. Mean ICBD score was 5.8±1.3 points. Neurological involvement was the most frequent manifestation in this group. Genital ulcers were more frequent in the non-ophthalmological involvement group. Systemic clinical domains are shown in Figure 1. The most frequent ocular manifestations were uveitis (n=44, 88.0%), retinal vasculitis (n=5, 10%) and dry eye (n=5, 10%). Likewise, the most frequent type of uveitis was anterior (n=17, 38.6%), followed by posterior uveitis (n=14, 31.8%). 26 (59.1%) of all uveitis were unilateral. Panuveitis was more frequent among patients under 60 years. Similarly, anterior uveitis was predominant in patients older than 70 years. There were no remarkable differences between genders. Main clinical features are shown in Table 1. Table 1. Clinical characteristics of ocular Behçet’s disease. n (% ) Unilateral, n (% ) Bilateral, n (% ) Uveitis 44 (88.0) 26 (59.1) 18 (40.9)  Anterior 17 (38.6) 13 (76.5) 4 (23.5)  Intermediate 2 (4.5) - 2 (100)  Posterior 14 (31.8) 9 (64.3) 5 (35.7)  Panuveitis 11 (25.0) 4 (36.4) 7 (73.6) Retinal vasculitis 5 (10.0) - - Dry eye 5 (10.0) - - Cystoid macular edema 4 (8.0) - - Episcleritis 3 (6.0) 3 (100) - Optic neuritis 2 (4.0) - - Conclusion: Ophthalmological involvement in Behçet’s disease was more frequent in men. Uveitis and retinal vasculitis were the most frequent ocular manifestation. No remarkable differences in clinical features were observed between genders. References: [1]Atienza-Mateo B, et al. Arthritis Rheumatol. 2019; 71(12):2081-2089. doi: 10.1002/art.41026 [2]Martín-Varillas JL, et al. Ophthalmology. 2018; 125(9):1444-1451. doi: 10.1016/j.ophtha.2018.02.020 [3]Atienza-Mateo B, et al. Rheumatology (Oxford). 2018;57(5):856-864. doi: 10.1093/rheumatology/kex480 [4]Vegas-Revenga N, et al. Am J Ophthalmol. 2019;200:85-94. doi: 10.1016/j.ajo.2018.12.019 [5]Calvo-Río V, et al. Clin Exp Rheumatol. 2014;32(4 Suppl 84): S54-7. PMID: 25005576 [6]Santos-Gómez M, et al. Clin Exp Rheumatol. 2016;34(6 Suppl 102): S34-S40. PMID:27054359 Figure 1. Comparison between clinical domains in patients with and without ophthalmological involvement. Disclosure of Interests: Alba Herrero-Morant: None declared, Guillermo Suárez-Amorín: None declared, Rosalía Demetrio-Pablo: None declared, Lara Sanchez-Bilbao: None declared, Carmen Álvarez-Reguera: None declared, David Martínez-López: None declared, Raúl Fernández Ramón: None declared, José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Lilly, Janssen, and Celgene, M. Cristina Mata-Arnaiz: None declared, Miguel Á. González-Gay Speakers bureau: AbbVie, Pfizer, Roche, Sanofi, Lilly, Celgene and MSD, Grant/research support from: AbbVie, MSD, Jansen and Roche, Ricardo Blanco Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, Sanofi, Lilly and MSD, Grant/research support from: AbbVie, MSD, and Roche
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2021-eular.3478
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2021
    detail.hit.zdb_id: 1481557-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Mortality Reduction in Septic Shock by Plasma Adsorption (ROMPA): a protocol for a randomised clinical trial
    BMJ ; 2016
    In:  BMJ Open Vol. 6, No. 7 ( 2016-07), p. e011856-
    Details
    In: BMJ Open, BMJ, Vol. 6, No. 7 ( 2016-07), p. e011856-
    Type of Medium: Online Resource
    ISSN: 2044-6055 , 2044-6055
    URL: Article
    DOI: 10.1136/bmjopen-2016-011856
    Language: English
    Publisher: BMJ
    Publication Date: 2016
    detail.hit.zdb_id: 2599832-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    AB1215 EPIDEMIOLOGY AND CLINICAL PHENOTYPE OF BEHÇET’S DISEASE IN A WELL-DEFINED POPULATION OF NORTHERN SPAIN
    BMJ ; 2020
    In:  Annals of the Rheumatic Diseases Vol. 79, No. Suppl 1 ( 2020-06), p. 1898.2-1899
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 79, No. Suppl 1 ( 2020-06), p. 1898.2-1899
    Abstract: Considerable epidemiological variations in prevalence of Behçet’s disease (BD) have been reported. These disparities may either reflect geographical differences, methodological artifacts, changes over time or random fluctuations. In Spain, published BD’s epidemiological studies are scarce. Objectives: To study epidemiological and clinical domains of BD in a well-defined population of Northern Spain, as well as, to compare results with other regions. Methods: We included all consecutive 111 patients, diagnosed of definitive or possible BD by expert rheumatologists between 1980 and 2019. Two Classification criteria were applied: a) International Study Group (ISG) for BD (Lancet. 1990; 335:1078-80 ), and b) International Criteria for BD (ICBD) (J Eur Acad Dermatol Venereol. 2014; 28:338-47 ). In addition, a literature review of Medline publications was carried out. Results: In our study, prevalence was higher than in most European populations regardless of the diagnostic criteria applied. Incidence was low (expert opinion: 0.021, ICBD: 0.016, ISG: 0.012). Mean age at onset (36.8±13.2) and gender distribution (55.9% females) were similar to other countries. Pathergy test was performed in 9% of patients giving low results (25.2%). Clinical domains’ frequency was in line with other regions except vascular and gastrointestinal involvement, which were lower. ( TABLE ) Conclusion: BD’s prevalence in Northern Spain is higher than in most European populations. These differences likely reflect a combination of true geographic variation, methodological artifacts as well as the easy access to Public Health System and its efficiency. In contrast, clinical phenotypes are similar to other regions. TABLE Diagnostic criteria and study period n cases / population size Mean age at onset and sex (%females) Prevalence (over 100000) / incidence Oral / genital ulcers (%) Skin lessions/ pathergy test (%) Ocular involvement (%) Joint involvement (%) Neurobehcet/ Vascular/ Gastrointestinal involvement (%) Herrero, A et al. Southern Europe (Cantabria, Spain) Expert opinion, ISG, ICBD / 1980-2019 111 (expert opinion) / 86 (ICBD) / 65 (ISG) / 581078 36.8±13.2/ 55.9 19.1 (expert opinion), 14.8 (ICBD), 11.2 (ISG) / 0.021 (expert opinion), 0.016 (ICBD), 0.012 (ISG) 99 / 53.1 68.4 / 25. 2 35.1 68.5 18 / 10 / 4.5 Calamia, K. T. et al. North America (Minnesota, USA) ISG / 1960-2005 13 / NR 31 / 30 5.2 / 0.38 100 / 62 85 / NR 62 46 23 / 23 / NR Altenburg, A. et al. Northern Europe (Berlin, Germany) ISG and ABD classification tree / 1961-2005 590 / 3391344 26 / 58 4.9 / 1 (estimated) 98.5 / 63.7 62.5 / 33.7 58.1 53 10.9 / 22.7 / 11.6 Mohammad, A. et al. Northern Europe (Skane County, Sweden) ISG / 1997-2010 40 / 809317 30.5 / 33 4.9 / 0.2 100 / 80 88 / NR 53 40 0 / 20 / NR Mahr, A. et al. Southern Europe (Seine-Saint-Denis County, France) ISG / 2003 79 / 1094412 27.6 / 43 7.1 / NR 100 / 80 90 / 20 51 59 10 / NR / 10 Salvarani, C. et al. Southern Europe (Reggio Emilia, Italy) ISG, 1988-2005 18 / 486961 33 / 50 3.7 / 0.24 100 / 78 100 / NR 56 50 11 / 6 / NR Azizlerli, G. et al. Middle East (Istambul, Turkey) ISG / prevalence study 101 / 23986 NR / 48.5 42 / NR 100 / 70.2 Not globally reported / 69.3 27.7 Not globally reported NR / Not globally reported / NR Davatchi, F. et al. Middle East (Iran nationwide) Expert opinion / 1975-2018 7641 / NR 25.6 / 44.2 80 / NR 97.5 / 64.4 62.2 / 50.4 55.6 38.1 3.9 / 8.9 / 6.8 Krause, I. et al. Middle East (Galilee, Israel) ISG / 15 years (not specific years have been reported) 112 / 737000 30.6 / 47 15.2 / NR NR / 68 41 / 44.4 58 70 11.6 / Not globally reported / NR Nishiyama, M. et al. Asia (Japan nationwide) 1987 JCBD / 1991 3316 / NR 35.7 / 50.6 NR / NR 98.2 / 73.2 87.1 / 43.8 69.1 56.9 11 / 8.9 / 15.5 Disclosure of Interests: Alba Herrero Morant: None declared, Guillermo Suárez Amorín: None declared, Lara Sanchez Bilbao: None declared, Carmen Álvarez Reguera: None declared, David Martínez-López: None declared, José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Janssen and Celgene, Speakers bureau: Pfizer and Lilly, Patricia Setien Preciados: None declared, M. Cristina Mata Arnaiz: None declared, Rosalía Demetrio-Pablo: None declared, Miguel Ángel Gordo Vega: None declared, Miguel Á. González-Gay Grant/research support from: AbbVie, MSD and Roche, Speakers bureau: AbbVie, MSD and Roche, Ricardo Blanco Grant/research support from: Abbvie, MSD and Roche, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2020-eular.4694
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2020
    detail.hit.zdb_id: 1481557-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    SAT0523 BIOLOGICAL THERAPY IN REFRACTORY ATYPICAL OPTIC NEURITIS. MULTICENTER STUDY
    BMJ ; 2020
    In:  Annals of the Rheumatic Diseases Vol. 79, No. Suppl 1 ( 2020-06), p. 1217.1-1218
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 79, No. Suppl 1 ( 2020-06), p. 1217.1-1218
    Abstract: Optic Neuritis (ON) is an inflammation of the optic nerve. Its most common presentation is demyelinating typical ON. Atypical ON is rare, severe, non-demyelinating and can be isolated or associated to different diseases including autoimmune diseases. If it is not treated, it can lead to devastating visual results. Conventional treatment includes systemic corticosteroids and conventional immunosuppressants (CIS). Objectives: Our aim was to assess the efficacy of biological therapy in atypical ON refractory to conventional treatment. Methods: Open-label multicenter study including 19 patients diagnosed with atypical ON refractory to systemic corticosteroids and at least one CIS. The main outcomes assessed were Best Corrected Visual Acuity (BCVA) and optic nerve and ganglionar cells Optical Coherence Tomography (OCT). These outcome variables were recorded at baseline, 1 week, 2 weeks, 1 month, 3 months and 6 months and 1 year after biological therapy onset. FIGURE Results: We studied 19 patients (12 women/7 men); mean age of 34.8 ± 13.9 years. The underlying diseases were idiopathic (n=7), Behçet´s disease (n=5), systemic lupus erythematosus (n=2), neuromyelitis optica (n=3), sarcoidosis (n=1) and relapsing polychondritis (n=1) (TABLE). Before biological therapy and besides systemic corticosteroids, patients had received different CIS. Biological therapy was adalimumab (n=6), rituximab (n=6), infliximab (n=5) and tocilizumab (n=4). After biological therapy, an improvement in ocular parameters was observed: BCVA [0.7±0.3 to 0.8±0.3; p= 0.03], optic nerve OCT [123.2±58.3 to 190.5±175.4; p= 0.11] , and ganglionar cells OCT [369.6±137.4 to 270.7±23.2; p= 0.03] at one year (FIGURE ). After a mean follow-up of 29.1 ±19.2 months, there were no severe adverse effects observed. Conclusion: Biological therapy may be effective in patients with refractory atypical ON. TABLE Case Gender/ Age Underlying disease Laterality IV steroids dose (g) Maximum prednisone oral dose (g) Conventional immunosuppressants Biological therapy Adverse effects 1 F/29 Idiopathic Unilateral 4 60 AZA TCZ No 2 F/26 Idiopathic Bilateral 5.5 30 AZA TCZ No 3 F/13 Idiopathic Bilateral - 10 MTX ADA No 4 F/25 Idiopathic Bilateral 4 60 MTX IFX, TCZ No 5 F/24 Idiopathic Bilateral 0.5 60 MTX, AZA ADA No 6 M/14 Idiopathic Bilateral - 10 MTX ADA No 7 F/30 Vasculitis ANCA+ Unilateral 3 60 AZA, MMF, LFM, CFM RTX Yes 8 M/21 Behçet Bilateral - 60 MTX, AZA ADA Nausea Vomits 9 M/25 Behçet Unilateral 0.5 60 MTX, CyA ADA No 10 M/39 Behçet Unilateral 3 80 MTX, MMF IFX No 11 M/40 Behçet Unilateral - 80 MMF IFX No 12 M/37 Behçet Unilateral - 60 CyA IFX No 13 F/68 NMO Unilateral 2.5 30 CFM, AZA RTX No 14 F/41 NMO Unilateral 3 60 CFM RTX Infection 15 F/43 NMO Bilateral 5 60 AZA RTX Infusion reaction 16 F/56 SLE Unilateral - 60 HCQ, MMF, CFM RTX No 17 F/47 SLE Unilateral 5 60 HCQ, MMF RTX No 18 F/43 Relapsing polychondritis Bilateral 3 60 MTX, CFM IFX, TCZ No 19 M/41 Sarcoidosis Bilateral 3 40 AZA ADA No Disclosure of Interests: Alba Herrero Morant: None declared, Carmen Álvarez Reguera: None declared, Vanesa Calvo del Rio Grant/research support from: MSD and Roche, Speakers bureau: Abbott, Lilly, Celgene, Grünenthal, UCB Pharma, Olga Maíz Alonso: None declared, Ana Blanco Speakers bureau: Abbvie, J. Narváez: None declared, Santos Castañeda: None declared, Esther Vicente Speakers bureau: BMS, Roche., Susana Romero-Yuste: None declared, Rosalía Demetrio-Pablo: None declared, ANA URRUTICOECHEA-ARANA: None declared, J. L. García Serrano: None declared, J. L. Callejas Rubio: None declared, Norberto Ortego: None declared, Julio Sánchez: None declared, Paula Estrada: None declared, Iñigo Rua-Figueroa: None declared, David Martínez-López: None declared, José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Janssen and Celgene, Speakers bureau: Pfizer and Lilly, Miguel Á. González-Gay Grant/research support from: AbbVie, MSD and Roche, Speakers bureau: AbbVie, MSD and Roche, Ricardo Blanco Grant/research support from: Abbvie, MSD and Roche, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2020-eular.5122
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2020
    detail.hit.zdb_id: 1481557-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    AB0399 EPIDEMIOLOGY OF BEHÇET DISEASE IN A NORTHERN SPANISH HEALTH REGION
    BMJ ; 2021
    In:  Annals of the Rheumatic Diseases Vol. 80, No. Suppl 1 ( 2021-06), p. 1227.2-1228
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 80, No. Suppl 1 ( 2021-06), p. 1227.2-1228
    Abstract: Behçet disease (BD) is a systemic and potentially severe disease. Its incidence varies widely worldwide. In Spain, published BD’s epidemiological studies are scarce. Objectives: In a well-defined Northern Spanish population-based cohort, the aim of this study was a ) to estimate epidemiological variations, b ) clinical domains and c ) to compare our results with other regions. Methods: Study of unselected all consecutive patients diagnosed with definitive or possible BD by expert rheumatologists between 1980 and 2020 in our health region. Two classification criteria were applied: a ) International Study Group (ISG) for BD [1] , and b ) International Criteria for BD (ICBD) [2] . In addition, a literature review of Medline publications was carried out. Results: In this study, from a total of 120 patients diagnosed with BD by expert opinion (58 women/62 men), 96 met ICBD and 59 ISG criteria. Mean age of the cohort at diagnosis was 37.6±13.8 years similar to other countries, as well as sex distribution. Prevalence was higher than in most European populations regardless the diagnostic criteria applied: expert opinion (20.6), ICBD (16.5) or ISG (10.1) (TABLE 1). Incidence was lower (expert opinion: 0.022, ICBD: 0.018, ISG: 0.011). Clinical domains’ frequency was in line with other regions except vascular and gastrointestinal involvement, which were lower. TABLE 1. Diagnostic criteria and study period n cases / population size Mean age at onset and sex (%female ) Prevalence (over 100000) / incidence Oral / genital ulcers (% ) Skin lessions/ pathergy test (% ) Ocular involve ment (% ) Joint involve ment (% ) Neurobehcet/ Vascular/ Gastrointestinalinvolvement (% ) Sánchez. L et al. Southern Europe (Cantabria, Spain ) Expert opinion, ISG, ICBD / 1980- 2020 120 (expert opinion) / 96 (ICBD) / 59 (ISG) / 581641 37.6 ±13.8/ 48.3 20.6 (expert opinion), 16.5 (ICBD), 10.1 (ISG) / 0.022 (expert opinion), 0.018 (ICBD), 0.011 (ISG) 94.2 / 59.2 63.3 / 25. 2 41.6 65 10.8 / 11.6 / 6.6 Calamia, K. T. et al. North America (Minnesota, USA ) ISG / 1960-2005 13 / NR 31 / 30 5.2 / 0.38 100 / 62 85 / NR 62 46 23 / 23 / NR Altenburg, A. et al. Northern Europe (Berlin, Germany ) ISG and ABD classification tree / 1961-2005 590 / 3391344 26 / 58 4.9 / 1 (estimated) 98.5 / 63.7 62.5 / 33.7 58.1 53 10.9 / 22.7 / 11.6 Mohammad, A. et al. Northern Europe (Skane County, Sweden ) ISG / 1997-2010 40 / 809317 30.5 / 33 4.9 / 0.2 100 / 80 88 / NR 53 40 0 / 20 / NR Mahr, A. et al. Southern Europe (SeineSaint-Denis County, France ) ISG / 2003 79 / 1094412 27.6 / 43 7.1 / NR 100 / 80 90 / 20 51 59 10 / NR / 10 Salvarani, C. et al. SouthernEurope (Reggio Emilia, Italy ) ISG, 1988-2005 18 / 486961 33 / 50 3.7 / 0.24 100 / 78 100 / NR 56 50 11 / 6 / NR Azizlerli, G. et al. Middle East (Istambul, Turkey ) ISG / prevalence study 101 / 23986 NR / 48.5 42 / NR 100 / 70.2 Not globally reported / 69.3 27.7 Not globally reported NR / Not globally reported / NR Davatchi, F. et al. Middle East (Iran nationwide ) Expert opinion / 1975-2018 7641 / NR 25.6 / 44.2 80 / NR 97.5 / 64.4 62.2 / 50.4 55.6 38.1 3.9 / 8.9 / 6.8 Krause, I. et al. Middle East (Galilee, Israel ) ISG / 15 years (not specific years have been reported) 112 / 737000 30.6 / 47 15.2 / NR NR / 68 41 / 44.4 58 70 11.6 / Not globally reported / NR Nishiyama, M. et al. Asia (Japan nationwide ) 1987 JCBD / 1991 3316 / NR 35.7 / 50.6 NR / NR 98.2 / 73.2 87.1 / 43.8 69.1 56.9 11 / 8.9 / 15.5 JCBD: Japanese diagnostic Criteria of Behçet’s Disease; n : number of cases; NR: Not Reported Conclusion: BD’s prevalence in Northern Spain is higher than in most European populations. These differences likely reflect a combination of true geographic variation, methodological artifacts as well as the easy access to Public Health System and its efficiency. In contrast, clinical phenotypes are similar to other regions. References: [1] Lancet. 1990; 335:1078-80 [2] J Eur Acad Dermatol Venereol. 2014; 28:338-47 Disclosure of Interests: Lara Sanchez-Bilbao: None declared, Guillermo Suárez-Amorín: None declared, Carmen Álvarez-Reguera: None declared, Alba Herrero-Morant: None declared, David Martínez-López: None declared, José Luis Martín-Varillas: None declared, M. Cristina Mata Arnaiz: None declared, Rosalía Demetrio-Pablo: None declared, Miguel A González-Gay Speakers bureau: AbbVie, Pfizer, Roche, Sanofi, Celgene and MSD., Grant/research support from: AbbVie, MSD, Jansen and Roche, Ricardo Blanco Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD., Grant/research support from: AbbVie, MSD and Roche.
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2021-eular.3577
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2021
    detail.hit.zdb_id: 1481557-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...